Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05419726 · ClinicalTrials.gov registry record

Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.

A clinical trial of Obesity, sponsored by University of California, Los Angeles.

Recruiting
Registry status
20
Enrollment target
1
Study location

NCT05419726: Recruiting study of Obesity, sponsored by University of California, Los Angeles.

NCT05419726 is a study of Obesity that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 20 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05419726, a study of Obesity, is actively recruiting participants, sponsored by University of California, Los Angeles.

RECRUITING
Registry status
20 participants
Enrollment target
1
Study location

Study Summary

Glucagon like peptide (GLP-1) agonists, such as liraglutide, exenatide, and semaglutide, have been increasingly used as a medication to address the current twin epidemics of diabetes and obesity. Their activities include increasing insulin production by pancreatic beta cells, improving insulin sensitivity in muscles and weight loss. The mechanisms underpinning the weight loss caused by GLP-1 agonists have not yet been fully elucidated, but brown adipose tissue (BAT) appears to play an important role. We propose to assess BAT activity, using infrared thermography camera images, before individuals start weekly administration of semaglutide, at week 2-4, and week 18-20. We hypothesize that this GLP-1 agonist, semaglutide, will cause an increase in BAT activity and a corresponding increase in basal metabolic rate.

Primary Outcome

delta temperature

Conditions Studied

Interventions

  • DRUG Semaglutide Injectable Product (not provided by the study)

Study Locations (1)

California

  • UCLA Health - Los Angeles

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2023-02-01
Est. Completion 2026-02-01

What NCT05419726 shows while recruiting

NCT05419726 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which Semaglutide Injectable Product (not provided by the study) is the first listed.

NCT05419726 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT05419726 about?

NCT05419726 is a clinical study titled "Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.". Glucagon like peptide (GLP-1) agonists, such as liraglutide, exenatide, and semaglutide, have been increasingly used as a medication to address the current twin epidemics of diabetes and obesity. Their activities include increasing insulin production by pancreatic beta cells, improving insulin sensi...

What is the current status of trial NCT05419726?

This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2023-02-01. Estimated completion is 2026-02-01.

What conditions does trial NCT05419726 study?

This clinical trial studies the following conditions: Obesity.

What interventions are being tested in trial NCT05419726?

The interventions under investigation include: Semaglutide Injectable Product (not provided by the study) (DRUG).

Who is sponsoring clinical trial NCT05419726?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05419726 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05419726's enrollment target sits among peer trials

20 946th of 1053 higher than 80 of 1,053 other Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05419726, the US trial registry maintained by the National Library of Medicine. NCT05419726 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.